Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1985 Feb;53(2):208–215. doi: 10.1136/hrt.53.2.208

Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double blind comparison with placebo.

D R Glover, C G Wathen, R G Murray, M C Petch, A L Muir, W A Littler
PMCID: PMC481741  PMID: 2857088

Abstract

The clinical effects of the oral beta 1 partial agonist, prenalterol, were investigated in 37 patients (29 male, eight female; mean age 57 years) with chronic ischaemic left ventricular failure using a placebo controlled randomised double blind protocol over six months. All patients were limited by dyspnoea (New York Heart Association class III) despite treatment with digoxin and diuretics. Twenty eight patients completed the protocol. Moderate clinical improvement was seen in the prenalterol group, whereas there was little change in the placebo group. Bicycle exercise capacity increased over six months in the prenalterol and placebo groups but only achieved statistical significance for prenalterol when compared with baseline values. Maximum exercise heart rate was significantly reduced in the prenalterol group compared with placebo. Radionuclide left ventricular ejection fraction at rest and during exercise and cardiothoracic ratio showed no significant improvement in either group over six months. Prenalterol was well tolerated and produced no increase in frequency of angina or ventricular arrhythmias. Prenalterol produced clinical benefits and improved exercise tolerance while reducing exercise heart rate. A moderate placebo response was noted. The apparent beta blocking effect of prenalterol may be as important as the beta 1 agonist effect in producing these benefits. Prenalterol has, however, been withdrawn because of side effects in animals.

Full text

PDF
208

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold S. B., Byrd R. C., Meister W., Melmon K., Cheitlin M. D., Bristow J. D., Parmley W. W., Chatterjee K. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med. 1980 Dec 18;303(25):1443–1448. doi: 10.1056/NEJM198012183032503. [DOI] [PubMed] [Google Scholar]
  2. Benge W., Litchfield R. L., Marcus M. L. Exercise capacity in patients with severe left ventricular dysfunction. Circulation. 1980 May;61(5):955–959. doi: 10.1161/01.cir.61.5.955. [DOI] [PubMed] [Google Scholar]
  3. Braunwald E. Heart failure: pathophysiology and treatment. Am Heart J. 1981 Sep;102(3 Pt 2):486–490. doi: 10.1016/0002-8703(81)90736-5. [DOI] [PubMed] [Google Scholar]
  4. Bruschke A. V., Proudfit W. L., Sones F. M., Jr Progress study of 590 consecutive nonsurgical cases of coronary disease followed 5-9 years. II. Ventriculographic and other correlations. Circulation. 1973 Jun;47(6):1154–1163. doi: 10.1161/01.cir.47.6.1154. [DOI] [PubMed] [Google Scholar]
  5. Chatterjee K., Parmley W. W. Vasodilator therapy for chronic heart failure. Annu Rev Pharmacol Toxicol. 1980;20:475–512. doi: 10.1146/annurev.pa.20.040180.002355. [DOI] [PubMed] [Google Scholar]
  6. Colucci W. S., Alexander R. W., Williams G. H., Rude R. E., Holman B. L., Konstam M. A., Wynne J., Mudge G. H., Jr, Braunwald E. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med. 1981 Jul 23;305(4):185–190. doi: 10.1056/NEJM198107233050402. [DOI] [PubMed] [Google Scholar]
  7. Currie P. J., Kelly M. J., Middlebrook K., Federman J., Sainsbury E., Ashley J., Pitt A. Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure. Br Heart J. 1984 May;51(5):530–538. doi: 10.1136/hrt.51.5.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dawson J. R., Bayliss J., Norell M. S., Canepa-Anson R., Kuan P., Reuben S., Poole-Wilson P. A., Sutton G. C. Clinical studies with beta 2 adrenoceptor agonists in heart failure. Eur Heart J. 1982 Dec;3 (Suppl 500):135–141. [PubMed] [Google Scholar]
  9. Degen P. H., Ervik M. Determination of prenalterol in plasma and in urine by gas-liquid chromatography. J Chromatogr. 1981 Mar 13;222(3):437–444. doi: 10.1016/s0378-4347(00)84144-4. [DOI] [PubMed] [Google Scholar]
  10. Detry J. M., Decoster P. M., Brasseur L. A. Hemodynamic effects of Corwin (ICI 118,587), a new cardioselective beta-adenoceptor partial agonist. Eur Heart J. 1983 Aug;4(8):584–591. doi: 10.1093/oxfordjournals.eurheartj.a061524. [DOI] [PubMed] [Google Scholar]
  11. Erbel R., Meyer J., Lambertz H., Schweizer P., Voelker W., Krebs W., Braun G., Effert S. Hemodynamic effects of prenalterol in patients with ischemic heart disease and congestive cardiomyopathy. Circulation. 1982 Aug;66(2):361–369. doi: 10.1161/01.cir.66.2.361. [DOI] [PubMed] [Google Scholar]
  12. Fitzpatrick D., Ikram H., Nicholls M. G., Espiner E. A. Hemodynamic, hormonal and electrolyte responses to prenalterol infusion in heart failure. Circulation. 1983 Mar;67(3):613–619. doi: 10.1161/01.cir.67.3.613. [DOI] [PubMed] [Google Scholar]
  13. Franciosa J. A., Park M., Levine T. B. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol. 1981 Jan;47(1):33–39. doi: 10.1016/0002-9149(81)90286-1. [DOI] [PubMed] [Google Scholar]
  14. Hendry W. G., Comerford M. B., Besterman E. M. A dose response study with oral prenalterol in patients with chronic congestive cardiac failure. Clin Cardiol. 1984 Jan;7(1):23–28. doi: 10.1002/clc.4960070106. [DOI] [PubMed] [Google Scholar]
  15. Hutton I., Murray R. G., Boyes R. N., Rae A. P., Hillis W. S. Haemodynamic effects of prenalterol in patients with coronary heart disease. Br Heart J. 1980 Feb;43(2):134–137. doi: 10.1136/hrt.43.2.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ikram H., Fitzpatrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet. 1981 Sep 5;2(8245):490–493. doi: 10.1016/s0140-6736(81)90881-3. [DOI] [PubMed] [Google Scholar]
  17. Johnston G. D., McDevitt D. G. Is maintenance digoxin necessary in patients with sinus rhythm? Lancet. 1979 Mar 17;1(8116):567–570. doi: 10.1016/s0140-6736(79)91002-x. [DOI] [PubMed] [Google Scholar]
  18. Kendall M. J., Goodfellow R. M., Westerling S. Prenalterol--a new cardioselective inotropic agent. J Clin Hosp Pharm. 1982 Jun;7(2):107–118. doi: 10.1111/j.1365-2710.1982.tb01010.x. [DOI] [PubMed] [Google Scholar]
  19. Kupper W., Schütt M., Hamm C. W., Kuck K. H., Hanrath P., Bleifeld W. Haemodynamic and cardiac metabolic effects of the new beta 1 agonist prenalterol in patients with cardiac failure. Eur Heart J. 1983 Aug;4(8):573–583. doi: 10.1093/oxfordjournals.eurheartj.a061523. [DOI] [PubMed] [Google Scholar]
  20. Lambertz H., Meyer J., Erbel R. Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure. Circulation. 1984 Feb;69(2):298–305. doi: 10.1161/01.cir.69.2.298. [DOI] [PubMed] [Google Scholar]
  21. LeJemtel T. H., Keung E., Sonnenblick E. H., Ribner H. S., Matsumoto M., Davis R., Schwartz W., Alousi A. A., Davolos D. Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man. Circulation. 1979 Jun;59(6):1098–1104. doi: 10.1161/01.cir.59.6.1098. [DOI] [PubMed] [Google Scholar]
  22. Lee D. C., Johnson R. A., Bingham J. B., Leahy M., Dinsmore R. E., Goroll A. H., Newell J. B., Strauss H. W., Haber E. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med. 1982 Mar 25;306(12):699–705. doi: 10.1056/NEJM198203253061202. [DOI] [PubMed] [Google Scholar]
  23. Litchfield R. L., Kerber R. E., Benge J. W., Mark A. L., Sopko J., Bhatnagar R. K., Marcus M. L. Normal exercise capacity in patients with severe left ventricular dysfunction: compensatory mechanisms. Circulation. 1982 Jul;66(1):129–134. doi: 10.1161/01.cir.66.1.129. [DOI] [PubMed] [Google Scholar]
  24. Mattsson H., Hedberg A., Carlsson E. Basic pharmacological properties of prenalterol. Acta Med Scand Suppl. 1982;659:9–37. doi: 10.1111/j.0954-6820.1982.tb00833.x. [DOI] [PubMed] [Google Scholar]
  25. Murray R. G., Tweddel A. C., Martin W., Pearson D., Hutton I., Lawrie T. D. Evaluation of digitalis in cardiac failure. Br Med J (Clin Res Ed) 1982 May 22;284(6328):1526–1528. doi: 10.1136/bmj.284.6328.1526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Petch M. C. Digoxin for heart failure in sinus rhythm. Thorax. 1979 Apr;34(2):147–149. doi: 10.1136/thx.34.2.147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Petch M. C., Wisbey C., Ormerod O., Scott C., Goodfellow R. M. Acute haemodynamic effects of oral prenalterol in severe heart failure. Br Heart J. 1984 Jul;52(1):49–52. doi: 10.1136/hrt.52.1.49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Selzer A. Digitalis in cardiac failure. Do benefits justify risks? Arch Intern Med. 1981 Jan;141(1):18–19. [PubMed] [Google Scholar]
  29. Swedberg K., Hjalmarson A., Waagstein F., Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J. 1980 Aug;44(2):117–133. doi: 10.1136/hrt.44.2.117. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES